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Abstract: Secondary damage following spinal cord injury (SCI) leads to non-reversible lesions
and hampering of the reparative process. The local production of pro-inflammatory
cytokines such as TNF-α can exacerbate these events. Oligodendrocyte death also
occurs, followed by progressive demyelination leading to significant tissue
degeneration. Dental stem cells from human apical papilla (SCAP) can be easily
obtained at the removal of an adult immature tooth. This offers a minimally invasive
approach to re-use this tissue as a source of stem cells, as compared to biopsying
neural tissue from a patient with a spinal cord injury. We assessed the potential of
SCAP to exert neuroprotective effects by investigating two possible modes of action:
modulation of neuro-inflammation and oligodendrocyte progenitor cell (OPC)
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differentiation. SCAP were co-cultured with LPS-activated microglia, LPS-activated rat
spinal cord organotypic sections (SCOS) and LPS-activated co-cultures of SCOS and
spinal cord adult OPC. We showed for the first time that SCAP can induce a reduction
of TNF-α expression and secretion in inflamed spinal cord tissues and can stimulate
OPC differentiation via activin-A secretion. This work underlines the potential
therapeutic benefits of SCAP for spinal cord injury repair.
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 Brussels, Januray 8th 2018 
 
Dear Prof. Eichmann, 
 
My co-authors and I are pleased to submit a revised manuscript entitled “Stem cells from 
human apical papilla decrease neuro-inflammation and stimulate oligodendrocyte 
progenitor differentiation via activin-A secretion” that we would like to be considered for 
publication in Cellular and Molecular Life Sciences. 
 
We saw that the reviewers were enthusiastic about the submission, though had several 
suggestions and requests for additional data prior to publication. Following the reviewer’s 
advice, clarifications have been made in the manuscript. We also added a graph in figures 4 and 
5 showing the impact of SCAP and SCOS on OPC differentiation on the number of GalC 
positive cells versus the total number of cells. We corrected the mistakes in the references.  
 
All others comments have been fully addressed and the manuscript modified accordingly. We 
are grateful for the reviewer comments that, taken together, have substantially strengthened the 
manuscript  
 
Thank you for your consideration of this manuscript for publication in Cellular and Molecular 
Life Sciences. We look forward to your reply.  
Yours sincerely, 
Anne des Rieux 
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Manuscript Number:  CMLS-D-17-01172 
 
Article Title: Stem cells from human apical papilla decrease neuro-inflammation and stimulate 
oligodendrocyte progenitor differentiation via activin-A secretion. 
 
Journal Name: Cellular and Molecular Life Sciences 
 
 
COMMENTS FOR THE AUTHOR: 
 
Reviewer #1:  
 
This paper describes a study regarding possible molecular mechanisms how transplanted human 
apical papilla cells (SCAP) can improve reconstruction of spinal cord neuronal tissues after 
injury. By using several co-culture systems, the authors demonstrated that SCAP can reduce 
both expression and secretion of TNF-α, and stimulate OPC differentiation via activing-A 
secretion in inflamed spinal cord. It is interesting and worth publishing. The present manuscript 
is, however, lacking in several respects. 
 
 
Major points 
 
1- <Fig2> The authors claimed that SCAP induced a decrease in TNF-expression and secretion 
via interaction with LPS-activated BV-2 cells and spinal cord organotypic section (SCOS). To 
explain the phenomena, they also claimed a possible involvement of the mechanism that SCAP 
could induce an alternative activated microglia (arginase-positive M2 microglia) through 
secreting growth factors, cytokine, and etc… This reviewer thinks that data from Fig. 2b, and f 
should not be compatible with their theory, and that the authors should explain the discrepancy. 
 
The reviewer is right and we rephrased this part more precisely as an increase of arginase 
expression has been observed only in SCAP co-cultures with microglia.  
 
- p13:  
“SCAP could induce an alternatively activated microglia phenotype by secretion of active 
molecules such as HGF, TGF-β, IDO, PGE2 and cytokines like IL-10 and IL-4 [38,39].” 
 
Has been changed for: 
 
“SCAP could have an anti-inflammatory action by secretion of active molecules such as HGF, 
TGF-β, IDO, PGE2 and cytokines like IL-10 and IL-4 [38,39].” 
 
 
2- ELISA kit for TNF-α (Fig.2b, e) may detect both human and murine TNF-α, which should 
be described somewhere appropriate.  
 
The supplier tested the kit against human TNFa and did not observe cross-reactivity. However, 
we agree that this is an important element and this information has been added in the M&M 
section. 
 
- p8- TNF-α and activin-A quantification by ELISA. 
 
“The TNF-α ELISA kit has been tested against human TNF-α by the manufacturer and didn’t 
show cross-reactivity with human TNF-α.” 
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3  
 
 
3- ＜Fig.3＞ If SCAP has similar multi-potency as dental pulp stem cells, it can differentiate 
into MBP/GalC-positive oligodendrocytes. Although the authors described that no tissue with 
cell attachment was observed (p6, l55), SCAP should be labeled with fluorescent-dye and be 
monitored, especially for Fig.3-fig.5, to exclude the possibility that oligodendrocytes evaluated 
should not be involved SCAP-derived cells 
 
We are sorry but it seems the reviewer misunderstood the meaning of those sentences. 
In the mentioned sentence: “We checked that the cells attached properly by bright field 
microscopy but, as the inserts are designed for cell culture and were coated with collagen, no 
issue with cell attachment was observed (data not shown).” We really meant “issue” and not 
“tissue”. Our purpose was to say that “the SCAP attached properly on the insert” not that “the 
tissue didn’t include SCAP”.  
 
- p6: We changed the sentence to make it clearer. 
We checked that SCAP attached properly on the inserts by bright field microscopy. SCAP 
attached and spread on the inserts with the same morphology as when grown in culture flasks 
(data not shown). 
 
Regarding figure 3, it is possible that SCAP could differentiate into MBP positive cells. 
However, we checked the literature again and we didn’t find any evidence of it. It is true that 
DPSC have been reported to differentiate in Schwann cells (Martens, W., et al. (2014). "Human 
dental pulp stem cells can differentiate into Schwann cells and promote and guide neurite 
outgrowth in an aligned tissue-engineered collagen construct in vitro." Faseb J 28(4): 1634-
1643) but it was after 2 weeks and a very specific culture protocol.  
It was also described that it is possible to differentiate DSPC into OPC (Moayeri, A., et al. 
(2017). "Transdifferentiation of Human Dental Pulp Stem Cells Into Oligoprogenitor Cells." 
Basic Clin Neurosci 8(5): 387-394.) but here too, it required 12 days and specific culture 
conditions.  
Since the SCAP were co-cultured with the SCOS for 48h only, we think it is unlikely that the 
SCAP could migrate in the sections and differentiate into mature oligodendrocytes.  
 
In regard of this comment, we however, modified the title of the section as well as of the figure 
legend. 
- p10:  
“SCOS-SCAP co-culture promotes differentiation of OPC from SCOS” has been replaced by 
“SCOS-SCAP co-culture increased MBP staining in SCOS”. 
 
- p23: 
“Fig.3 SCOS-SCAP co-culture increases the expression of MBP in SCOS and induces activin-
A secretion.” 
 
Regarding Figure 5, the OPC we showed are the adult OPC from spinal cord that were seeded 
on coverslips under the inserts on which SCAP and SCOS were grown (see figure 1). As the 
porosity of the filter is 0.45 um, we are almost positive that no cells could have crossed the 
insert and that the GalC positive cells are only isolated rat adult OPC. 
  
 
＜Fig.4, 5＞ The authors evaluated differentiation of the oligodendrocytes by the positive area. 
These evaluations would be difficult to distinguish between morphological changes or 
percentages of the differentiated cells. This reviewer prefers expression with the percentage of 
positive cells against total cells. In addition, were survivals of the oligodendrocytes not altered 
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in all the experiments? Any cells migration were not observed from the insert to bottom of the 
dishes? 
 
As requested by the reviewer, we counted the number of positive cells vs the total number of 
cells and added this result to the manuscript (Fig 4c and 5d), although we believe that the 
positive area reflects better the extent of OPC differentiation. We thus propose to keep the 
graphs with the percentage of positive area in addition to the percentage of positive cells. 
 
Regarding Figure 4, whether we quantified the positive area or the positive cells, the 
conclusions remained the same.  
 
The text has been modified accordingly as followed: 
- p11:  
“The area of GalC+ staining was significantly higher, as well as the percentage of positive cells, 
when OPC were co-cultured with both SCOS and SCAP relative to OPC alone, SCAP and OPC 
or SCOS and OPC (Fig. 4 b and c, respectively). Consistent with the hypothesis that activin A 
promotes OPC differentiation, a higher activin-A concentration was detected only in culture 
media of SCOS cultured with SCAP and OPC compared to the other conditions (Fig. 4d).” 
 
Regarding Figure 5, the conclusions remain also similar whether we quantified the number of 
positive cells or the positive surface area, except for the fact that the difference between OPC-
SCOS-exogenous activing A and OPC-SCOS-SCAP was not significant. So, we can conclude 
that the percentage of GalC+ surface was higher when OPC were co-cultured with SCOS and 
SCAP than with SCOS and exogenous activin A but, regarding the percentage of positive cells, 
no significant difference was observed. So, exogenous activin A and SCAP induced the same 
number of GalC+ cells but the extent of the differentiation is higher with SCAP.  
 
The text has been modified accordingly as followed: 
- p12: 
When treated with exogenous activin A, the percentage of GalC+ cells and area tended to 
increase in OPC-SCOS cultures (Fig. 5c and d). The percentage of surface area significantly 
increased only when OPC were co-cultured with SCOS and SCAP (Fig. 5c), as the percentage 
of positive cells was not significantly different between activin A treated OPC-SCOS cultures 
and OPC-SCOS-SCAP tri-cultures (Fig. 5c). When treated with follistatin, the percentage of 
adult rat OPC that were GalC+ decreased significantly in the tri-cultures (Fig. 5b and d).  
 
In the discussion, we modified p15:  
“As the percentage of GalC+ area was higher in the tri-cultures than in cultures supplemented 
with exogenous activin-A, and as this percentage was reduced nonetheless at the same level by 
follistatin than in exogenous activin-A supplemented cultures, we concluded that activin-A was 
required but did not induce OPC differentiation alone.” 
 
Minor points 
 
p6, l55: no issue with cell attachment… → no tissue with cell attachment …. 
See answer to the comment above. 
 
 
Primers sets used in this study should correspond to individual figure. Otherwise, readers might 
misread meaning of the figures. 
We are not sure to exactly understand what the reviewer requires but we added a column in 
Table 1 with the figure number for which the primers were used and the accession numbers. 
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Data from statistical analyses as p-values should be indicated for all the figures. Instead of 
symbols of the p-value, there are semantic alphabetical-ordered symbols above each bar in all 
the figures.  
   
They are several ways of indicating significance. We allocated a different letter to conditions 
that are statistically different and the same letter to conditions that are not significantly different. 
It is, to our opinion, clearer than to have bars and stars crossing each other on the graphs, 
especially with multiple conditions. 
 
We modified the sentence in the “Statistical analysis” part explaining this with the hope that it 
is now clearer. We also added this information in the figure legends. 
- p9 and p23-24: 
Conditions not related by the same letter are significantly different.   
 
 
Reviewer #2:  
 
 
I would like to suggest that two of the studies mentioned in Methods (Gerardo-Nava et al, 2014; 
Bianco et al, 2017) be included in References. 
("Spinal cord organotypic slice cultures for the study of regenerating motor axon interactions 
with 3D scaffolds. 
Gerardo-Nava J1, Hodde D2, Katona I2, Bozkurt A3, Grehl T4, Steinbusch HW5, Weis J6, 
Brook GA) 
 
We are sorry for the issue with the references. It seems we had a problem with Endnote that 
resulted in these references missing. The problem has been fixed and we checked that all the 
references are in the text at their appropriate place and accurate. 
 
Bianco et al, 2017 is ref 26 and Gerardo-Nava et al, 2014 is ref 27. 
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Summary  
Secondary damage following spinal cord injury (SCI) leads to non-reversible lesions and hampering of 
the reparative process. The local production of pro-inflammatory cytokines such as TNF-α can 
exacerbate these events. Oligodendrocyte death also occurs, followed by progressive demyelination 
leading to significant tissue degeneration. Dental stem cells from human apical papilla (SCAP) can be 
easily obtained at the removal of an adult immature tooth. This offers a minimally invasive approach to 
re-use this tissue as a source of stem cells, as compared to biopsying neural tissue from a patient 
with a spinal cord injury. We assessed the potential of SCAP to exert neuroprotective effects by 
investigating two possible modes of action: modulation of neuro-inflammation and oligodendrocyte 
progenitor cell (OPC) differentiation. SCAP were co-cultured with LPS-activated microglia, LPS-
activated rat spinal cord organotypic sections (SCOS) and LPS-activated co-cultures of SCOS and 
spinal cord adult OPC. We showed for the first time that SCAP can induce a reduction of TNF-α 
expression and secretion in inflamed spinal cord tissues and can stimulate OPC differentiation via 
activin-A secretion. This work underlines the potential therapeutic benefits of SCAP for spinal cord 
injury repair. 
 
Keywords: Spinal cord, dental stem cells, inflammation, oligodendrocyte progenitor cells, 
differentiation 
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 3 
Introduction 
The cascade of secondary neuro-degenerative events following spinal cord injury (SCI) includes 
bleeding, necrotic or apoptotic processes and lesion area enlargement [1,2].  
Among these, inflammation has been highlighted as a key regulator of degeneration and regeneration. 
Independent studies have shown that immunosuppression is permissive for central nervous system 
(CNS) tissue restoration [3,4], while a beneficial role of inflammation on neuro-regeneration has also 
been described [5]. Both detrimental and favorable effects of the inflammatory response depend on 
the abundance of cell types (microglia and leukocytes), signaling molecules (chemokines and 
cytokines) and the post-traumatic time-line (acute, subacute or chronic phase) [5]. Microglial activation 
is associated with both detrimental and beneficial neuro-regenerative outcomes depending on their 
activation state [5]. The presence of pro-inflammatory cytokines, such as TNF-α, may enhance cell 
death and intensify secondary damage in SCI [6,7]. Furthermore, an increase in arginase-1 positive 
macrophages has already been associated with axon preservation, decrease of scar formation, 
increase in myelin sparing and functional recovery after SCI [8].  
Oligodendrocyte apoptosis, that can be induced by inflammation, in and around the lesion site leads to 
progressive demyelination, inducing axonal dysfunction and degeneration [9]. To restore the 
oligodendrocyte population, oligodendrocyte progenitor cell (OPC) proliferation and differentiation has 
to be activated. In the presence of pro-inflammatory cytokines and in the absence of growth promoting 
factors following SCI, remyelination is limited, among other factors, by impaired OPC differentiation 
[10]. Demyelination and inflammation are both crucial issues that must be addressed when developing 
therapeutic strategies aimed at the restoration of spinal cord function after injury.  
Mesenchymal stem cell (MSC)-based therapies have proved to be promising strategies for spinal cord 
repair. Indeed, MSC therapy allows for multi-targeted and environmentally responsive benefits [11,12]. 
The positive effects of MSC treatment for CNS diseases/disorders result from their ability to 
differentiate into neural cell lineages, secrete neurotrophic factors, reduce cell apoptosis and modulate 
inflammation [13]. MSC improve outcomes after neural trauma by inhibiting the activation of pro-
inflammatory microglia and by promoting their stimulation to an anti-inflammatory phenotype [14]. The 
pro-inflammatory phenotype of microglia has increased expression of pro-inflammatory cytokines such 
as TNF-α or IL-1β, whereas anti-inflammatory microglia releases neuroprotective factors including 
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 4 
anti-inflammatory cytokines (IL-10, IL-1 receptor antagonist) as well as neurotrophic factors (nerve 
growth factor and transforming growth factor β) [15].  
Human dental stem cells have been increasingly studied as an alternative source of MSC to bone 
marrow due to their accessibility, their neural crest origin and their high proliferation rate [16]. Indeed, 
dental stem cells can be easily isolated with a limited invasiveness and display a higher proliferation 
rate and expression of specific neural stem cell transcripts and proteins than bone marrow-derived 
MSC [17,18]. Although SCAP are less studied and exploited than dental pulp stem cells (DPSC), they 
have a greater migratory and tissue regenerative capacity, as well as higher proliferative potential [19]. 
SCAP can regulate trigeminal nerve outgrowth in vitro and support an increased hind limp muscle 
strength in a rat spinal cord injury model [20]. We showed that implantation of SCAP embedded in 
their original niche (whole apical papilla tissue) into a rat hemi-section SCI model promoted functional 
recovery [21].   
Activin-A is a member of the transforming growth factor β superfamily. It presents plethoric effects that 
has been extensively studied in various organs but it was only recently that Miron et al. showed that 
activin-A stimulates OPC differentiation. In addition, activin-A has an anti-inflammatory effect and is 
produced by alternatively-activated macrophages [22]. Jeong et al. showed that activin-A is 
constitutively expressed in healthy spinal cord and that levels increased up to 4 days post-injury to 
decrease again at day 7 [23]. Activin-A is synthesized by either neurons or inflammatory cells (possibly 
macrophages) or both and thus may participate in the protection of neuronal tissues after SCI. 
Additionally, activin-A levels increased in astrocytes and oligodendrocytes at the peripheries of SCI 
lesions [23]. Thus, activin A may protect glial cells, in addition to neurons, in either a paracrine or 
autocrine manner [23]. 
In this study, we examined the in vitro and ex vivo impact of SCAP on microglia activation and OPC 
differentiation. We demonstrated that SCAP can reduce the expression and secretion of TNF-α in an 
LPS-activated microglial cell line, and in LPS-activated spinal cord tissue. In addition, we showed that 
OPC differentiate when co-cultured with spinal cord tissue and SCAP, due, at least partially, to activin-
A secretion. This study provides evidence that SCAP could support spinal cord repair by a 
neuroprotective action, driven by reduction of pro-inflammatory cytokines and the stimulation of OPC 
differentiation via activin-A secretion.  
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Methods 
SCAP culture  
Human SCAP were isolated from a healthy donor wisdom tooth and characterized [24]. SCAP were 
used between passages 5 and 8 [24,25]. SCAP were cultured in minimum essential medium eagle 
(MEM, Sigma-Aldrich, St Louis, USA) supplemented with 10 % fetal bovine serum (FBS), 1 % L-
glutamine (ThermoFisher, Merelbeke, Belgium), 1 % Penicillin/Streptomycin (PEST) (ThermoFisher) 
(SCAP medium). Cells were either grown in normoxia (N) in 21 % O2 and 5 % CO2 or in hypoxia (H) in 
1 % O2 and 5 % CO2 (InVivo2 400 hypoxia Workstation, Ruskinn, Bridgend, UK). SCAP medium was 
equilibrated at 1 % O2 before medium change for SCAP grown in hypoxia.  
 
BV-2 mouse microglial cell culture  
BV-2 cells (ATCC) were maintained in Dulbecco’s modified eagle’s medium (DMEM) with GlutamaxTM 
(ThermoFisher), supplemented with 10 % FBS (Sigma-Aldrich) and 1 % PEST (BV-2 medium) at 37 
°C in 21 % O2 and 5 % CO2. BV-2 cells were seeded in 24-well plates at a density of 5x105 cells/well. 
 
OPC isolation and culture 
All animal-related experiments were approved by the local ethical committee for animal care 
(2016/UCL/MD/011). OPC were isolated and plated as previously described [26]. Briefly, adult Wistar 
rat spinal cords were isolated and dissociated into single cells through enzymatic digestion with 
trypsin-EDTA (ThermoFisher). The cell suspension was then strained, centrifuged and the resulting 
pellet re-suspended in DMEM/F12 containing 1 % PEST, 10 mM HEPES buffer (ThermoFisher), 10 
ng/ml FGF2 (PeproTech, Rocky Hill, USA), 10 ng/ml platelet-derived growth factor-AA (PDGFAA) 
(PeproTech), and 10 ng/ml IGF-I (PeproTech) and plated in uncoated culture flasks. Fresh growth 
factors were added every other day, and media was changed completely after 7 days of culture. Free 
floating OPC spheres were collected and passaged following dissociation with Accutase® 
(ThermoFisher). OPC (4th passage) were seeded as single cells onto poly-D-lysine (PDL) (Sigma-
Aldrich) coated 13 mm glass coverslips at a density of 10.000 cells/cm2 following dissociation of 
spheres with Accutase®. For seeding, cells were maintained in their growth media with the addition of 
0.5 % FBS for 60 minutes to allow the cells to adhere. Seeded coverslips were then transferred to a 30 
mm petri dish (3 coverslips per dish) and maintained in SCAP medium. 
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Spinal cord organotypic section (SCOS) preparation and culture 
Spinal cords of P7 Wistar rats were extracted, dissected as previously described [27] and 350 µm 
sections were transversally cut with a tissue chopper (McIlWain Tissue Chopper, The Mickle 
Laboratory Engineering Co. Ltd., Surrey, UK). Four sections were placed on type I collagen-coated (10 
μg/cm2, Sigma-Aldrich) Millicell® Organotypic Cell Culture Inserts (Merck Millipore, Billerica, USA). 
One ml of medium consisting of 48.37 % MEM, 24.18 % horse serum, 24.18 % HBSS (ThermoFisher)) 
supplemented with 2 % D-glucose, 0.97 % GlutamaxTM, 0.97 % PEST, 1.21 % HEPES and 0.12 %  
amphotericin B (Thermofisher) (pH 7.4, SCOS medium) was added in the lower compartment of each 
insert. SCOS were maintained at 37 °C in a humidified incubator for 2 weeks before use. Medium was 
changed 24 hours after the dissection and then twice a week until SCOS were used for the 
experiments.  
 
BV-2 cells-SCAP co-culture and activation by LPS  
BV-2 cells (5x105 cells/well) were seeded in 24 well plates. Eight hours later, resting cells were 
stimulated by incubation with 100 ng/ml of lipopolysaccharides from Escherichia coli (LPS, O55:B5) 
(Sigma-Aldrich) for 16 hours. SCAP previously grown in normoxia or hypoxia were then added to the 
LPS-activated BV-2 cells at the same density (5x105 cells/well). The BV-2 cells-SCAP co-cultures were 
maintained in SCAP medium supplemented with 100 ng/ml of LPS at 37 °C in normoxia for 48 hours. 
LPS-activated BV-2 cells cultured without SCAP and non-activated BV-2 cells were used as controls 
(N=3, n=4). 
 
SCOS-SCAP co-culture and activation by LPS  
SCAP grown in normoxia and hypoxia (2x105 SCAP/insert in 200 µl of SCAP media) were co-cultured 
with SCOS by seeding them on the upper side of inserts (Fig.1a). Medium was changed from SCOS 
medium to SCAP medium and cells were allowed to attach on the inserts for 8 hours. We checked that 
SCAP attached properly on the inserts by bright field microscopy. SCAP attached and spread on the 
inserts with the same morphology as when grown in culture flasks (data not shown). 
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 (data not shown). The medium was then changed for SCAP medium containing LPS (100 ng/ml). Co-
cultures were maintained for 48 hours before analysis. LPS-activated SCOS cultured without SCAP 
and non-activated SCOS were used as controls (N=3; n=4-5). 
 
SCOS-SCAP-OPC tri-culture and activation by LPS  
SCAP cultured in either normoxia or hypoxia were seeded on the inserts as described above. 
Coverslips seeded with adult rat OPC were placed under seeded inserts (3 coverslips per insert). 
Medium was then changed for serum-free SCAP medium supplemented with LPS (100 ng/ml) 
(Fig.1b). Cultures were maintained for 7 days before analysis. OPC without SCOS or without SCAP 
were used as controls (N=3, n=3-4).  
 
Impact of activin-A inhibition on OPC differentiation 
SCOS-SCAP-OPC were tri-cultured as described above. Follistatin, a natural activin-A inhibitor [28], 
was added in the lower compartment of SCOS-SCAP-OPC cultures (50 ng/ml for 48 hours and then 
10 ng/ml for 3 days (R&D system, Minneapolis, USA)). Cultures were maintained for 7 days before 
analysis. Cultures of SCAP alone, OPC alone, SCAP with OPC, and SCOS with OPC were used as 
controls. OPC alone, SCOS-OPC and SCOS-SCAP-OPC were supplemented with exogenous 
recombinant activin-A at the same concentration as detected using enzyme-linked immunosorbent 
assay (ELISA) in SCOS-SCAP supernatants (10 ng/ml) and were used as positive controls (N= 2, 
n=3). 
 
RNA extraction and real-time qPCR 
For mRNA analysis, media was removed and TriPure reagent (Roche, Basel, Switzerland) was added 
to each well of BV2 cells or co-/tri-cultures at the end of the incubation period. Regarding SCOS, each 
section was carefully picked up and placed in a 0.5 ml tube with TriPure. The plates were then stored 
at -80°C for later assessment. Total RNA was extracted using the TriPure reagent according to the 
manufacturer's instructions. cDNA was synthesized using a reverse transcription kit (Promega 
corporation, Leiden, The Netherlands) from 1 μg of total RNA. qPCR was performed with a STEP one 
PLUS instrument and software (Applied Biosystems, Foster City, CA, USA) as previously described 
[29]. Data were normalized to the 60S ribosomal protein L19 (RPL19) mRNA expression for the BV-2 
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 8 
cells, and to the 60S ribosomal protein L13 (RPL13) mRNA expression for the SCAP and SCOS. For 
each experiment, the absence of treatment effect on reference gene expression was verified. Primer 
sequences and accession numbers are listed in table 1. Primers were designed to study the gene 
expression of activin-A. Activin-A mRNA sequence shows substantial homology between rodents and 
humans, however the mRNA sequence of human Activin-A is longer. Thus, primers were designed 
specifically for human activin-A (human specific primers) while it was not possible to design primers 
specific for rat activin-A. Therefore, the designed primers were able to recognize human, rat and 
mouse activin-A (universal primers). 
 
TNF-α and activin-A quantification by ELISA 
TNF-α and activin-A were quantified in undiluted cell supernatants using a Murine TNF-α Standard 
TMB ELISA Development Kit (PeproTech) and a DuoSet ELISA kit (R&D System, Abingdon, UK), 
respectively. The TNF-α ELISA kit has been tested against human TNF-α by the manufacturer and 
didn’t show cross-reactivity with human TNF-α. ELISA assays were performed as recommended by 
the manufacturer. TNF-α was quantified 48 hours after treatment in BV-2 cells-SCAP and SCOS-
SCAP co-cultures. Activin-A was quantified 48 hours after treatment in SCOS-SCAP co-cultures and 
in SCOS-SCAP-OPC tri-cultures (N=3, n=3-5). All measurements were performed in duplicate. 
 
Immunofluorescence 
SCOS were stained for Myelin Basic Protein (MBP), chemokine (C-C motif) ligand 1 (CCL1) and 
neural/glial antigen 2 (NG2) after co-culture with SCAP. SCOS were fixed in 4 % paraformaldehyde 
(PFA) for 1 hour and rinsed twice in PBS. Samples were blocked for 1 hour at room temperature in 2.5 
% horse serum containing 0.03 % triton X100 and incubated with primary antibodies at room 
temperature for 1 hour (Table 2). Sections were then washed in PBS and incubated for 2 hours at 
room temperature with the secondary antibodies (Table 2). Native OPC were identified by NG2 
immunoreactivity and mature oligodendrocytes by MBP immunoreactivity. 
OPC derived from adult rat spinal cord were stained for GalC after tri-culture with SCOS and SCAP. 
OPC were fixed in 4 % PFA for 10 minutes, washed with PBS and incubated in blocking solution (2 % 
bovine serum albumin, 10 % normal goat serum, and 0.03 % Triton X100 in PBS) for 1 hour. Samples 
were incubated with primary antibodies diluted in blocking solution (Table 2) for 1 hour at room 
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temperature. After being washed in PBS, coverslips were incubated with secondary antibodies (diluted 
in PBS containing 0.5 % BSA, Table 2) for 1 hour at room temperature. Negative controls were 
performed by omitting primary antibodies. Vectashield hardset (containing 4’, 6-diamidino-2-
Phenylindole, dihydrochloride (DAPI)) (Vectorlabs, Burlingame, CA) was used as mounting medium. 
Quantification of positive cell number and area was performed on 3 random images per coverslips. 
MBP and GalC positive staining was quantified using Volocity (Perkin Elmer, Coventry, UK) and 
ImageJ (1.43u, National Institutes of Health, Bethesda, MD, USA), respectively. 
 
Statistical analysis 
Statistical analyses were performed using GraphPad PRISM (GraphPad Software, San Diego, CA, 
USA). One-way analysis of variance (ANOVA) with an appropriate post-hoc test was performed. 
Paired T-test was performed for MBP quantification. Error bars represent the standard error of the 
mean in all figures. Statistical significance was accepted at the 5 % level (p-value < 0.05). Conditions 
not related by the same letter are significantly different. “N” and “n” indicate number of independent 
experiments and number of biological replicates, respectively. Between 3 and 5 sections per condition 
were analyzed depending of the total number of sections isolated from rat spinal cords. 
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Results 
SCAP modulate the expression of inflammatory markers 
The impact of SCAP on TNF-α and arginase-1 expression was investigated in LPS-activated BV-2 
cells (microglia). Spinal cord lesions present a hypoxic environment that could impact MSC behavior 
and its secretome [30]. We previously demonstrated that hypoxia induced an up-regulation of SCAP 
gene expression of neurotrophic factors [25]. Thus, we assessed the impact of SCAP hypoxia-
preconditioning treatment on their immunomodulatory properties.  
LPS treatment induced an increased expression of TNF-α, while decreasing the expression of 
arginase-1 in comparison to non-activated BV-2 cells (supplementary data a and b). Co-culture of 
SCAP with LPS-treated BV-2 cells induced a significant decrease of TNF-α mRNA expression (Fig. 
2a) and secretion (Fig. 2b) compared to BV-2 cells cultured alone. There was no influence of SCAP 
culture condition (i.e. hypoxia or normoxia). Arginase-1 mRNA expression was increased in BV-2 cells 
when co-cultured with SCAP relative to BV-2 mono-cultures. This effect was more pronounced when 
BV-2 cells were cultured with SCAP grown in normoxia than when cultured with SCAP grown in 
hypoxia (Fig. 2c).  
The same experiment was performed to evaluate the effect of SCAP on TNF-α and arginase-1 mRNA 
expression by LPS-activated SCOS. This culture model enables the preservation of the basic 
cytoarchitecture and neuronal-glial interactions [31], while allowing us to assess responses of both 
endogenous and exogenous cells as well as their interactions [32]. SCAP, whether grown in normoxia 
or hypoxia, were able to adhere to inserts and displayed a normal cell morphology compared to cells 
grown in flasks (data not shown). LPS treatment of SCOS induced an increased expression of TNF-α 
mRNA compared with gene expression of non-activated SCOS (supplementary data c). Co-culture of 
SCAP (grown in normoxia or hypoxia) with LPS-treated SCOS significantly decreased TNF-α 
expression (Fig. 2d) compared to SCOS cultured alone. A significant decrease of TNF-α secretion was 
observed in the supernatants of SCOS co-cultured with SCAP in comparison to SCOS alone (Fig. 2e). 
However, SCAP co-culture with SCOS did not influence arginase-1 gene expression (Fig. 2f).  
 
SCOS-SCAP co-culture increased MBP staining in SCOS  
Remyelination is a key regenerative process, promoting functional recovery following SCI [33-35]. 
Therefore, proliferation and differentiation of OPC is crucial to restore and maintain myelin. Co-culture 
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of SCOS with SCAP showed an increase in staining for mature oligodendrocyte markers (MBP and 
CC1 positive cells) in SCOS compared to SCOS alone (Fig. 3a). Pixel quantification showed that 
significantly more cells were positive for MBP in SCOS-SCAP co-cultures than in SCOS alone (Fig. 
3b).  
 
SCOS-SCAP co-culture induces activin-A expression and secretion 
Since SCAP co-culture with SCOS increased OPC to oligodendrocyte differentiation, we assessed the 
expression and secretion of activin-A in co-cultures in the presence of LPS. SCAP and SCOS cultured 
alone expressed activin-A (Fig. 3c and d). A significant increase of human activin-A gene expression 
was observed when SCAP were co-cultured with SCOS compared to SCAP alone (Fig. 3c). Using 
primers that recognized both human and rat activin-A, we observed that co-culture of SCAP with 
SCOS also showed a significant increase of activin-A gene expression (Fig. 3d). Importantly, SCAP 
co-culture with SCOS induced a higher concentration of activin-A in supernatants compared to SCAP 
or SCOS alone (Fig. 3e). No effect of hypoxia was observed on activin-A expression (Supplementary 
data d) so only SCAP grown in normoxia were used for the following experiments.  
 
SCOS-SCAP promotes adult OPC differentiation 
To confirm the impact of SCAP on adult spinal cord OPC differentiation, we developed an original tri-
culture model where SCAP and SCOS were co-cultured with OPC isolated from adult rat spinal cord 
(Fig. 1b). The area of GalC+ staining was significantly higher, as well as the percentage of positive 
cells, when OPC were co-cultured with both SCOS and SCAP relative to OPC alone, SCAP and OPC 
or SCOS and OPC (Fig. 4b and c, respectively). Consistent with the hypothesis that activin A 
promotes OPC differentiation, a higher activin-A concentration was detected only in culture media of 
SCOS cultured with SCAP and OPC compared to the other conditions (Fig. 4d).  
  
Activin A produced by SCAP and SCOS co-culture induces OPC differentiation 
We next investigated whether activin-A was responsible for OPC differentiation by treating the cultures 
with the activin-A-sequestering protein follistatin, which prevents its action and its detection by ELISA. 
Follistatin impact on activin-A concentration in culture media was first evaluated, and we observed that 
follistatin was able to reduce the amount of activin-A detected in the medium of the tri-cultures (Fig. 
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5a). We observed a similar effect of follistatin when exogenous activin-A was added to the cultures 
(Fig. 5a (grey bars)), confirming activin-A inhibition by follistatin.  
When treated with exogenous activin A, the percentage of GalC+ cells and area tended to increase in 
OPC-SCOS cultures (Fig. 5c and d). The percentage of surface area significantly increased only when 
OPC were co-cultured with SCOS and SCAP (Fig. 5c), as the percentage of positive cells was not 
significantly different between activin A treated OPC-SCOS cultures and OPC-SCOS-SCAP tri-
cultures (Fig 5c). When treated with follistatin, the percentage of adult rat OPC that were GalC+ 
decreased significantly in the tri-cultures (Fig. 5b and d).  
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Discussion 
 
Stem cells can stimulate tissue repair primarily via two mechanisms: cell replacement and secretion of 
bioactive molecules. MSC have been described to have immunomodulatory properties [13] but little 
information is available on dental stem cells, and in particular SCAP, a promising source of MSC for 
CNS repair. In this study, we demonstrate that SCAP impact microglial function and stimulate OPC 
differentiation in the presence of a pro-inflammatory stimuli. We also showed for the first time that 
SCAP express activin-A and that this expression was increased in the presence of inflamed spinal 
cord tissue. We established a link between activin-A secretion by SCAP-SCOS and the differentiation 
of adult spinal cord OPC into mature oligodendrocytes.  
LPS treatment stimulated TNF-α expression and secretion by both BV-2 cells and SCOS. The impact 
of LPS on BV-2 cells has been extensively described by others [36,37] but this is the first time that 
spinal cord organotypic cultures have been used to study the impact of stem cells on the activation of 
spinal cord tissue. We showed that when SCOS were treated with 100 ng/ml of LPS, gene expression 
for TNF- significantly increased. Thus, SCOS reactivity to LPS makes this ex-vivo model a useful tool 
to study the effect of new therapies on neuro-inflammation.  
We demonstrated that SCAP induced a decrease in TNF-α expression and secretion in LPS-activated 
BV-2 cells and SCOS. The ability of two types of dental stem cells (dental pulp stem cells and stem 
cells from human exfoliated deciduous teeth) to reduce secretion of pro-inflammatory cytokines like 
TNF has already been described [38,39] but little is known about SCAP. SCAP could have an anti-
inflammatory action by secretion of active molecules such as HGF, TGF-β, IDO, PGE2 and cytokines 
like IL-10 and IL-4 [40,41]. MSC could also act via extracellular vesicles containing miRNA (i.e. miRNA 
146 and 155) or via an EV surface molecule like PD-L1 or galectin-1 [42]. Another possible 
explanation could be the production of TNF-stimulated gene 6 protein (TSG-6), a protein that inhibits 
the NF-kB and MAPK activation pathway, by SCAP activated by LPS-treated microglial cells. 
Expression of pro-inflammatory cytokines such as TNF-α increases during the acute phase (first 
hours) of SCI and exacerbates secondary tissue degeneration [43,44]. TNF-α induces neuron and 
oligodendrocyte apoptosis [43], lesion area enlargement and promotes Wallerian degeneration [9]. 
Down-regulation of TNF-α has also been linked with greater neuronal survival and reduced apoptosis 
[7]. Furthermore, MSC have been reported to reduce BV-2 cell proliferation and TNF-α expression 
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following LPS stimulation [37,45]. Similarly, our data demonstrates the impact of SCAP on pro-
inflammatory cytokine expression. The transplantation of MSC after SCI has already been correlated 
with an increase of alternatively activated macrophages (i.e. arginase-1 positive cells) that were 
associated with functional recovery [8]. Stem cells from human exfoliated deciduous teeth have been 
reported to be associated with the induction of an anti-inflammatory macrophage phenotype when 
injected into the spinal cord after injury. This effect was attributed to the secreted proteins MCP-1 and 
ED-Siglec-9 [46]. Thus, SCAP could protect the spinal cord after injury by acting on macrophages and 
microglia, limiting damage that is associated with prolonged inflammation. 
We observed that culturing SCAP in hypoxia did not offer any advantage but was not detrimental to 
their immunomodulation properties nor to their activin-A expression (supplementary data d). Although 
Jiang and colleagues reported that MSC can be grown in hypoxia to enhance their immunomodulatory 
properties, migration, proliferation, and survival [47], these effects depend on the origin of the MSC, 
the serum used [48] and O2 tension under which the study was performed [49]. Since SCAP properties 
are not limited by hypoxia, we may expect that local hypoxic conditions in spinal cord lesion should not 
affect their immunomodulation properties while supporting neurotrophic factor production. 
It has already been demonstrated that dental stem cells could support remyelination in vitro and in vivo 
[50,51]. In addition, other dental stem cells (dental pulp stem cells and stem cells from human 
exfoliated deciduous teeth) demonstrate neuro-regenerative properties, which they exert via different 
mechanisms, including the prevention of neural apoptosis, the blocking of axon growth inhibitors, and 
the replacement of dead oligodendrocytes [51]. These findings suggest that dental stem cells could 
promote remyelination after SCI. Our objective was thus to evaluate the impact of SCAP on adult OPC 
differentiation via paracrine actions. To that end, we developed an innovative tri-culture model 
composed of SCAP, SCOS and isolated adult OPC from rat spinal cord. This model can be used to 
investigate and optimize treatments for SCI before resorting to the more challenging in vivo SCI 
models. We showed that SCAP, when associated with spinal cord tissue, promoted the differentiation 
of adult OPC into mature oligodendrocytes. MSC have been described to support remyelination, 
reduce demyelination and cell loss by decreasing the astroglial response and apoptosis in a cuprizone 
model [52]. The mechanisms involved are not clearly elucidated yet but the positive action of MSC are 
attributed to the protection of damaged axons and immunomodulation.  
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This study reports, for the first time, that activin-A is expressed by SCAP and SCOS. Moreover, we 
showed that activin-A was expressed by both SCAP and SCOS separately, but that the interaction of 
SCAP and SCOS induced a higher degree of activin-A expression and secretion. Djouad and 
colleagues observed that activin-A secretion by MSC, as well as the activin-A:follistatin ratio, depends 
on their origin [53]. Activin-A expression is required for the maintenance of stemness and the 
regulation of MSC functions. Activin-A also plays a functional role in the suppression of inflammatory 
or immune processes [54]. A correlation between activin-A and MSC-mediated immunosuppression 
has been made and suggested that lower concentrations of activin-A produced by tonsil-derived-MSC 
(compared with other MSC types), corresponded to their significantly lower immunosuppressive 
potential [53]. Activin-A produced by human umbilical cord-derived MSC suppressed interferon 
gamma (INF-γ) production by natural killer cells [55]. An up-regulation of activin-A has been observed 
in the early stage of SCI [23]. This higher level of activin-A was correlated with neuroprotection and 
immunomodulation, potentially by stimulating proliferation of alternatively activated macrophages [23]. 
In the present study, a significant increase of activin-A concentration in the medium of SCAP-SCOS 
co-cultures correlated with increased MBP staining in SCOS. Recently, it has been shown that activin-
A stimulates OPC differentiation to MBP positive oligodendrocytes [22]. In support of the earlier report, 
we demonstrated that OPC differentiation was correlated with increased activin-A production, which 
was enhanced by the presence of SCAP. Interestingly, we observed that the presence of spinal tissue 
was indispensable for the increased activin-A secretion and OPC differentiation. Our findings suggest 
the presence of a potential synergy between SCAP and spinal tissue that leads to an increase of 
activin-A production and OPC differentiation.  
In order to determine if activin-A secreted by SCAP/SCOS was solely responsible for OPC 
differentiation, we treated the tri-cultures with follistatin. This protein inhibits activin-A actions by 
forming a complex consisting of one activin-A dimer and two follistatin molecules, thus preventing 
activin-A from binding to its receptor [28]. Activin-A was no longer detected by ELISA when culture 
supernatants were supplemented with follistatin, confirming that the majority of activin-A had been 
sequestered and inactivated. Also, blocking activin-A with follistatin in tri-cultures suppressed OPC 
differentiation, which was not rescued when exogenous activin-A was added in absence of SCAP. As 
the percentage of GalC+ area was higher in the tri-cultures than in cultures supplemented with 
exogenous activin-A, and as this percentage was reduced nonetheless at the same level by follistatin 
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than in exogenous activin-A supplemented cultures, we concluded that activin-A was required but did 
not induce OPC differentiation alone. Supporting this hypothesis is the fact that as follistatin is mostly 
known to inhibit activin-A, it also inhibits factors from the TGF superfamily such as the bone 
morphogenic proteins [56]. It may be hypothesized that SCAP produce other essential bioactive 
molecules that stimulate OPC differentiation along with activin-A, the actions of which are also 
inhibited by follistatin. Several other related factors, such as growth factors (e.g. PDGF, IGF-1) or 
cytokines (e.g. TGF-β1, CXCL12), have been reported to induce OPC differentiation [57] and could, 
therefore, be involved in this phenomenon.  
 
This study highlights the neuroprotective potential of SCAP via two mechanisms: modulation of neuro-
inflammation and the promotion of OPC differentiation to mature oligodendrocytes. For the first time, 
we demonstrate that SCAP, in association with spinal tissue, produce activin-A and that this protein 
supports OPC differentiation. Our data demonstrate that SCAP may provide therapeutic benefits for 
treating acute SCI. 
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Tables 
Table1. Primer sequences 
Gene 
name 
Accession 
number 
Cell 
type 
Forward primer (5’-3’) Reverse primer (3’-5’) Figure 
 Rat RPL13 NM_173340.2 SCOS GGCTGAAGCCTACCA
GAAAG 
CTTTGCCTTTTCCTT
CCGTT 
Fig 2 d 
& f, 3 d 
Rat 
Arginase 
NM_017134.3 SCOS GAAGGTCTCTACATC
ACAGAAGAAA 
CAAGGTCAACGCCA
CTGC 
Fig 2 f 
Rat TNF-α NM_012675.3 SCOS AGTGACAAGCCCGTA
GCC 
TTGAAGAGAACCTG
GGAGTAGA 
Fig 2 d 
Mouse 
RPL19 
NM_009078.2 BV-2 
cells 
GAAGGTCAAAGGGAA
TGTGTTCA 
CCTTGTCTGCCTTCA
GCTTGT 
Fig 2 a 
& c 
Mouse 
Arginase 
NM_007482.3 BV-2 
cells 
GGTTCTGGGAGGCCT
ATCTT 
TGAAAGGAGCCCTG
TCTTGT 
Fig 2 c 
Mouse 
TNF-α 
NM_013693.3 BV-2 
cells 
AGCCCCCAGTCTGTA
TCCTT 
GGTCACTGTCCCAG
CATCTT 
Fig 2 a 
Human 
RPL13 
NM_012423.3  SCAP CATAGGAAGCTGGGA
GCAAG 
GCCCTCCAATCAGT
CTTCTG 
Fig 3 c 
Human 
Activin 
NM_002192.3 SCAP TCCCTTGTGAGCCTT
GAATC  
CCTGGGTAATTGGG
TAGGAAAG 
Fig 3 c 
UNIVERSA
L Activin 
NM_002192.3 
(Human) 
NM_017128.2 
(Rat) 
NM_008380.2 
(Mouse) 
SCOS 
and 
SCAP 
TCATCACCTTTGCCGA
GTCA 
CTGGTTCTGTTAGC
CTTGGG 
Fig 3 d 
 
When several variants exist, the primers were designed to recognize all variants. 
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Table2. List of antibodies used for immunofluorescence analysis. 
Primary 
antibody 
Dilution Supplier Secondary antibody Dilution Supplier 
MBP 1:250 BioRada anti-rat IgG2a Alexa 555 
(mouse) 
1:1000 Life Technologiesd 
CC1 1:100 Abcamb anti-mouse Alexa 647 1:1000 Life Technologiesd 
NG2 1:200 Merck Milliporec anti-rabbit IgG Alexa 
488 (goat) 
1:1000 Life Technologiesd 
GalC 1:800 Merck Milliporec anti-mouse IgG3 Alexa 
594 (goat) 
1:400 Life Technologiesd 
aBioRad, Hercules, USA 
bAbcam, Cambridge, UK 
cMerck Millipore, Temecula, CA 
dLife Technologies, Eugene, OR, USA 
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Figure legend  
 
Results obtained for LPS treated samples are presented in this manuscript while results for non-LPS 
treated samples are in supplementary data. In all figures, groups without SCAP are presented in white, 
groups with SCAP grown in normoxia (N) in light grey and groups with SCAP grown in hypoxia (H) in 
dark grey. 
 
Fig.1 Graphical experimental plan  
A: Co-culture model of SCOS with SCAP on insert. B: Tri-culture model of SCOS with SCAP on 
inserts and with OPC isolated from adult rat spinal cord seeded on coverslips.   
 
Fig.2 SCAP modulate the inflammatory markers gene expression and secretion 
A-C: SCAP impact on LPS-activated BV-2 cells, 48h after incubation. A: SCAP impact on TNF-α gene 
expression of BV-2 cells evaluated by RT-qPCR (N=2, n=4). B: Impact of SCAP co-cultured with BV-2 
cells on BV-2 cells TNF-α production in culture media (ELISA) (N=2, n=4). C: SCAP impact on 
arginase-1 gene expression of BV-2 cells (N=2, n=4). D-F: SCAP impact on LPS-activated SCOS, 48h 
after incubation. D: Impact of SCAP on SCOS TNF-α gene expression (N=2, n=4). E: Impact of SCAP 
co-cultured with SCOS on TNF-α production in culture media (ELISA) (N=2, n=4). F: Impact of SCAP 
on SCOS arginase gene expression (N=2, n=4). Conditions not related by the same letter are 
significantly different. 
 
Fig.3 SCOS-SCAP co-culture increased the expression of MBP in SCOS and induces activin-A 
secretion 
A: OPC were identified in SCOS by immunofluorescence using NG2 (green) staining and 
oligodendrocytes were identified using MBP (red) and CC1 (white) staining. B: MBP positive pixels 
were quantified in SCOS cultured with and without SCAP (N=2, n=3). C: Activin-A gene in SCAP 48h 
after incubation with SCOS (N=2, n=3). B:  Activin-A gene expression in SCOS 48h after incubation 
with SCAP (N=2, n=3). C: Activin-A quantification in culture media using ELISA (N=3, n=3). Conditions 
not related by the same letter are significantly different. 
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Fig.4 SCOS-SCAP promotes adult OPC differentiation and induces activin-A secretion 
A: Oligodendrocytes were identified by immunofluorescence using GalC staining 7 days after 
incubation of adult rat spinal cord OPC with SCOS and SCAP. B: GalC positive pixels were quantified 
by ImageJ software (N=2, n=3 (3 pictures/coverslips)). C: Activin-A quantification in culture media after 
48h of incubation (ELISA) (N=3, n=3). Conditions not related by the same letter are significantly 
different. 
 
Fig.5 Activin-A produced by SCAP and SCOS induces OPC differentiation  
A: Activin-A quantification in culture media (ELISA) 48h after incubation (N=2, n=3). B: 
Oligodendrocytes were identified by immunofluorescence using GalC staining 7 days after incubation. 
C: GalC positive pixels were quantified by ImageJ software (N=2, n=3 (3 pictures/coverslips)). 
Conditions not related by the same letter are significantly different. 
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